2025/09/08
TaiMed Biologics (4147) Invited to Share Antibody Therapeutics R&D and Manufacturing Strategies at Biologics CDMO Asia 2025
2025/07/25
TaiMed Biologics (4147) Invited to Share Key Business Priorities and Strategic Plan at the 2025 Taiwan Biotech Industry Summit Forum
2025/07/15
TaiMed Biologics (4147) invited to participate in the Taiwan Biotech Industry Summit Forum
2025/07/04
TaiMed Biologics(4147) Confirms Continuity of Trogarzo® Partnership Amidst Future Pak Acquisition of Theratechnologies
2025/06/30
TaiMed Biologics (4147) has been selected to Present Research on Novel CD4+ Cell-Targeting Antibody-Drug Conjugates for HIV Treatment at ID Week 2025
2025/06/22
TaiMed Biologics has initiated Phase IIb Clinical Study Protocol Preparation of Long-Acting HIV Therapy TMB-365/380 to the U.S. FDA
2025/06/10
TaiMed Biologics Signs MOU with NTU School of Pharmacy to Launch Internship and Talent Development Program
2025/04/30
TaiMed Biologics Signed CDMO Service Agreement with U.S. Client, Adding Growth Momentum to Operations
2025/04/09
On April 2, 2025, the United States announced the implementation of a reciprocal tariff policy on countries and regions worldwide. This has no significant impact on the company's operations.
2025/04/02
Macau Pharmaceutical Administration Bureau Approves TaiMed Bologics’ Trogarzo as the First and Only Monoclonal Antibody for the Treatment of HIV
2025/04/02
Dr. Jimmy Chang, CEO of TaiMed Biologics interviewed by BioWorld
2025/03/13
TaiMed marketing partner, Theratechnologies Inc announcement of presentation from Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
2025/03/12
TaiMed Biologics to Present Late-Breaking Phase IIa Data at CROI 2025 on Long-Acting TMB-365/TMB-380 Regimen for HIV Maintenance Therapy.
2025/03/06
TaiMed Biologics and Helios Pharmaceutical Company Limited Partner to Commercialize Trogarzo® in Vietnam
2025/03/05
TaiMed Biologics Invests in Marigold Therapeutics to Advance Antibody-Drug Conjugate (ADC) Drug Development